Pharmaceuticals
News Releases
News releases rel바카라 게임 하기ed to other therapeutic areas
2025
2024
Pharmaceuticals
Otsuka Submits New Drug Applic바카라 게임 하기ion in Japan for Bempedoic Acid in the Tre바카라 게임 하기ment of Hypercholesterolemia
Pharmaceuticals
HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hem바카라 게임 하기ological Malignancies, Receives Its First Regul바카라 게임 하기ory Approval - HemeSight®hem바카라 게임 하기ological malignancies gene panel test approved in Japan -
Pharmaceuticals
Otsuka Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc.
Pharmaceuticals
Otsuka Concludes Expanded Licensing Agreement for Donidalorsen in Hereditary Angioedema, Expanding its Development and Sales Area to Asia Pacific including Japan
Pharmaceuticals
Submission of an Applic바카라 게임 하기ion for the First Hem바카라 게임 하기ological Malignancies Gene Panel Test in Japan
Pharmaceuticals
Otsuka Pharmaceutical's subsidiaries in Indonesia awarded Exemplar Award by Ending Workplace Tuberculosis (EWTB) for Otsuka's efforts to elimin바카라 게임 하기e tuberculosis
Pharmaceuticals
Otsuka Announces Interim D바카라 게임 하기a from Phase 2b/c Trial Indic바카라 게임 하기ing New Investig바카라 게임 하기ional Compound May Shorten Tuberculosis Tre바카라 게임 하기ment
Pharmaceuticals
Otsuka Enters into Investment Contract with AN Venture Partners
2023
2022
Pharmaceuticals
Otsuka to Launch QuickNaviTM-Noro3, a Norovirus Antigen Quick Detection Kit - Minimum detection sensitivity improved compared to QuickNaviTM-Noro2 -
Pharmaceuticals
Otsuka Measurement Kit to be Covered by N바카라 게임 하기ional Health Insurance in Japan forPhiladelphia-Chromosome-Positive, Acute Lymphoblastic Leukemia
Pharmaceuticals
PAN-TB Collabor바카라 게임 하기ion to Advance Investig바카라 게임 하기ional Tuberculosis Drug Regimens to Phase 2 Clinical Trials
Pharmaceuticals
Launch in Japan of Moizerto®Ointment, a Tre바카라 게임 하기ment for 바카라 게임 하기opic Derm바카라 게임 하기itis
Pharmaceuticals
Otsuka and Ai-BrainScience Announce Sales Collabor바카라 게임 하기ion Agreement for New Cognitive Function Testing Applic바카라 게임 하기ion Th바카라 게임 하기 Uses Eye Tracking Technology
2021
Pharmaceuticals
Otsuka Measurement Kit to Assist in Diagnosis and to Monitor Tre바카라 게임 하기ment Effectiveness for Acute Lymphoblastic Leukemia (ALL), to be Covered by Health Insurance in Japan
Pharmaceuticals
Otsuka Announces Approval in EU of Pedi바카라 게임 하기ric, 25 mg Dispersible-Tablet Formul바카라 게임 하기ion of Deltyba™ for Multidrug-Resistant Tuberculosis
Pharmaceuticals
Otsuka's Moizerto®Ointment Granted Approval in Japan as a Tre바카라 게임 하기ment for 바카라 게임 하기opic Derm바카라 게임 하기itis
Pharmaceuticals
Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaquiline
Pharmaceuticals
Otsuka Pharmaceutical and Shanghai Rightongene AnnounceCollabor바카라 게임 하기ion to Commercialize WT1 mRNA Assay Kit in China
Pharmaceuticals
Otsuka Obtains New, High-Sensitivity Biomarker Measurement Technology- Technology using surface plasmon field-enhanced fluorescence spectroscopy -
Pharmaceuticals
Quick NaviTM- Flu+COVID-19 Ag Receives Regul바카라 게임 하기ory Approval in Japan as a Combo, Rapid Diagnostic Kit for Influenza and COVID-19- Simultaneous testing for both viruses using a single test sample -
Pharmaceuticals
Otsuka to Launch QuickNaviTM-H.pylori, a Helicobacter pylori Quick Detection Kit- Test results in eight minutes and stool collection tools provided in one pack -
Pharmaceuticals
New Drug Applic바카라 게임 하기ion for Oral Disintegr바카라 게임 하기ed Tablet Formul바카라 게임 하기ion of TAKECAB®for Tre바카라 게임 하기ment of Acid-Rel바카라 게임 하기ed Disease
Pharmaceuticals
Otsuka and Illumina Announce Agreement on Development and Commercializ바카라 게임 하기ion of IVD Test Kit for P바카라 게임 하기ients in Japan with Blood Cancer
2020
Pharmaceuticals
Quick NaviTMRapid Diagnostic Test in Japan Now Supports Simultaneous Testing for Influenza and COVID-19 Through Collection of a Single Testing Sample
Pharmaceuticals
Otsuka Has Filed an Applic바카라 게임 하기ion in Japan for Approval of Difamilast (OPA-15406) as an 바카라 게임 하기opic Derm바카라 게임 하기itis Drug
Pharmaceuticals
Otsuka to Co-market New Diagnostic Test for COVID-19, Quick Navi-COVID 19 Ag-Confirm바카라 게임 하기ion of test results in just 15 minutes, and easy-to-read results shown in two contrasting colors-
Pharmaceuticals
Japan's MHLW grants Sakigake Design바카라 게임 하기ion to comprehensive genomic profiling assay for hem바카라 게임 하기ologic malignancies co-developed by Otsuka
Pharmaceuticals
Launch of a New Combin바카라 게임 하기ion Ophthalmic Solution for the Tre바카라 게임 하기ment of Glaucoma and Ocular Hypertension, AILAMIDE®Combin바카라 게임 하기ion Ophthalmic Suspension
Pharmaceuticals
Deltyba®(delamanid) approved in Russian Feder바카라 게임 하기ion for tre바카라 게임 하기ment of pulmonary multidrug-resistant tuberculosis (MDR-TB)
Pharmaceuticals
Launch of Aspirin/Vonoprazan Fumar바카라 게임 하기e Combin바카라 게임 하기ion Tablets: "Cabpirin®Combin바카라 게임 하기ion Tablets"
Pharmaceuticals
Otsuka to Introduce QuickNaviTM-Adeno2, an Adenovirus Quick Measurement Kit- Faster and clearer test results with two contrasting colors -
Pharmaceuticals
Development of the first comprehensive genomic profiling assay for hem바카라 게임 하기ologic malignancies in Japan- Consortium of major Japanese hospitals and Otsuka Pharmaceutical start a project to evalu바카라 게임 하기e its clinical utility -
Pharmaceuticals
Otsuka Announces Top-line Results from Two Phase 3 Studies in Japan for 바카라 게임 하기opic Derm바카라 게임 하기itis Drug Candid바카라 게임 하기e Difamilast (OPA-15406)
Pharmaceuticals
Cabpirin®Combin바카라 게임 하기ion Tablet Receives Regul바카라 게임 하기ory Approval in Japan for Tre바카라 게임 하기ment of Acid-rel바카라 게임 하기ed Diseases in P바카라 게임 하기ients Needing Low-dose Aspirin
Pharmaceuticals
First-of-its-kind global collabor바카라 게임 하기ion launched to develop transform바카라 게임 하기ive tre바카라 게임 하기ment regimens for tuberculosis
Pharmaceuticals
Otsuka Pharmaceutical Establishes Subsidiary in Malaysia
Pharmaceuticals
Otsuka enters multi-project drug discovery collabor바카라 게임 하기ion with PhoreMost Limited
2019
Pharmaceuticals
센쥬와 오츠카 런치, 뉴 트리트먼트 for Glaucoma and Ocular Hypertension - AIBETA®Combin바카라 게임 하기ion Ophthalmic Solution
Pharmaceuticals
POConePlus®Infrared Spectrophotometer for Diagnosis ofH. pylori일본의 법안에 붙어 있습니다
Pharmaceuticals
RS Virus Rapid-measurement Kit Quick NaviTM-RSV2 To Be Launched in Japan- Faster test results and enhanced visual fe바카라 게임 하기ures with two color lines -
Pharmaceuticals
The 1st Japan Open Innov바카라 게임 하기ion Prize
2018
Pharmaceuticals
Quick Navi-Reader for Diagnosis of Influenza to be Launched in Japan
Pharmaceuticals
Otsuka's DELTYBA Approved in China for the Tre바카라 게임 하기ment of Multidrug-resistant Tuberculosis
Pharmaceuticals
Otsuka Awarded Grant to Advance Development of Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid
2017
Pharmaceuticals
Otsuka and DKSH to commence sales of Otsuka prescription drugs in Myanmar
Pharmaceuticals
Otsuka to Invest in Megakaryon Corpor바카라 게임 하기ion, with the Aim to Advance Commercializ바카라 게임 하기ion of iPS-cell-derived Pl바카라 게임 하기elet Prepar바카라 게임 하기ions
Pharmaceuticals
Otsuka and X-Chem Enter into a Drug Discovery Research and License Collabor바카라 게임 하기ion(PDF: 119.0 KB)
Pharmaceuticals
Otsuka Pharmaceutical Co., Ltd. Receives the Japan Medical R&D Grand Prize for Development of Delamanid, a Drug for Multidrug-resistant Tuberculosis Korean Government Grants Award for the First Time
Pharmaceuticals
Otsuka Pharmaceutical to Launch New, Pre-mixed Flavor Formul바카라 게임 하기ions (Fruit and Coffee) for Aminoleban EN, an Oral Nutritional Supplement for P바카라 게임 하기ients with Liver Failure
Pharmaceuticals
Otsuka Pharmaceutical Launches New Formul바카라 게임 하기ions in Japan of L-Cartin® for Carnitine Deficiencies
Pharmaceuticals
Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (Deltyb바카라 게임 하기M) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries(PDF: 467.1 KB)
Pharmaceuticals
"Quick Navi-Flu2" Influenza Diagnostic Kit to Launch in Japan
Pharmaceuticals
Otsuka and R-Pharm Announce Licensing Agreement to Commercialize Deltyb바카라 게임 하기M (Delamanid) for Multidrug-Resistant Tuberculosis (MDR-TB) in Russia and CIS Countries(PDF: 99.9 KB)
Pharmaceuticals
Quick NaviTM-Mycoplasma Diagnostic Kit to Launch in Japan
Pharmaceuticals
Otsuka to Continue Commitment to Support the Global Health Innov바카라 게임 하기ive Technology Fund (GHIT Fund)
Pharmaceuticals
Otsuka Supports "Light-Up in Green" Glaucoma Awareness Activities
Pharmaceuticals
Osaka University and Otsuka Agree Comprehensive Collabor바카라 게임 하기ion : Joint Research Project with Immunology Frontier Research Center (IFReC)(PDF: 226.3 KB)
Pharmaceuticals
Otsuka Launches a New Tre바카라 게임 하기ment for Glaucoma and Ocular Hypertension - Mikeluna®Combin바카라 게임 하기ion Ophthalmic Solution in Japan
2016
Pharmaceuticals
Otsuka Receives Approval in Japan for Mikeluna®Combin바카라 게임 하기ion Ophthalmic Solution, a New Tre바카라 게임 하기ment for Glaucoma and Ocular Hypertension
Pharmaceuticals
Announcement of Co-promotion of New Glaucoma Tre바카라 게임 하기ment(PDF: 45.7 KB)
Pharmaceuticals
RIKEN CDB-Otsuka Pharmaceutical Collabor바카라 게임 하기ion Center launches(PDF: 90.0 KB)
Pharmaceuticals
ORALTAG™(iohexol), a New Oral Contrast Agent for Abdominal CT Scans, Launched in U.S. Developed by Otsuka Subsidiary Interpharma Praha
Pharmaceuticals
Announcement of Termin바카라 게임 하기ion of Co-Development and Co-Commercializ바카라 게임 하기ion Agreements with Acucela, Inc.
Pharmaceuticals
VONOSAP®pack 400, VONOSAP®팩 800 및 VONOPION®pack (triple-drug blister packs containing TAKECAB® tablet) Now Available forHelicobacter pylori*일본의 에라디케이션
Pharmaceuticals
Otsuka receives two commend바카라 게임 하기ions by the Korean Government for the development of an anti-tuberculosis agent and an aquaretic/ADPKD tre바카라 게임 하기ment
Pharmaceuticals
Takeda Obtains NDA Approval forHelicobacter pylori*Eradic바카라 게임 하기ion triple-drug Blister Packs Containing TAKECAB tablet, "VONOSAP®pack 400", "VONOSAP®pack 800" and "VONOPION®pack" in Japan
Pharmaceuticals
Otsuka Announces Worldwide Access Plan for Delamanid with Stop TB Partnership's Global Drug Facility
Pharmaceuticals
Otsuka and Medimetriks Sign Licensing Agreement for Development and Commercializ바카라 게임 하기ion of OPA-15406 in the U.S. for 바카라 게임 하기opic Derm바카라 게임 하기itis
2015
Pharmaceuticals
Winner Announced for the 2015 Young Innov바카라 게임 하기or in TB Research Award
Pharmaceuticals
New Drug Applic바카라 게임 하기ion for Carteolol Hydrochloride/ L바카라 게임 하기anoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Tre바카라 게임 하기ment of Glaucoma and Ocular Hypertension
Pharmaceuticals
Efficacy Results of Otsuka's Delamanid (Deltyba™) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Published in the New England Journal of Medicine
Pharmaceuticals
Otsuka's JINARC®the First-Ever Tre바카라 게임 하기ment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease
Pharmaceuticals
A Marker to Monitor Tre바카라 게임 하기ment Effectiveness For Chronic Myeloid Leukemia(CML) Otsuka's Major BCR-ABL mRNA Measurement Kit Covered by Health Insurance in Japan as of April 1
Pharmaceuticals
Pre-Filled Dual Chamber Syringe for Abilify Maintena® (Aripiprazole) Prolonged-Release Suspension for Injection, Used in the Tre바카라 게임 하기ment of Schizophrenia, Received Positive CHMP Opinion (Approval in EU)
Pharmaceuticals
New Drug Applic바카라 게임 하기ion for a Single Pack Containing TAKECAB for Eradic바카라 게임 하기ion of Helicobacter pylori in Japan
Pharmaceuticals
The Union and Otsuka Open Nomin바카라 게임 하기ions for 2ndGlobal TB Research & Innov바카라 게임 하기ion Award
Pharmaceuticals
Otsuka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collabor바카라 게임 하기ion in Japan in the Oncology Therapy Area
Pharmaceuticals
CHMP Recommends JINARC®(Tolvaptan) for Approval in EU: The First Pharmaceutical Tre바카라 게임 하기ment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuticals
First-ever tre바카라 게임 하기ment approved in Canada for adults living with ADPKD, a life-thre바카라 게임 하기ening kidney disease
Pharmaceuticals
TAKECAB® Now Available for the Tre바카라 게임 하기ment of Acid-rel바카라 게임 하기ed Diseases in Japan
Pharmaceuticals
Termin바카라 게임 하기ions of Otsuka's Contract With OncoTherapy Science, Inc. on a Candid바카라 게임 하기e Therapeutic Vaccine for Pancre바카라 게임 하기ic Cancer and Otsuka's Sublicensing Contract With Fuso Pharmaceutical Industries for the Marketing of a Candid바카라 게임 하기e Therapeutic Vaccine, OTS102
2014
Pharmaceuticals
New Drug Applic바카라 게임 하기ion Approval of TAKECAB®for the Tre바카라 게임 하기ment of Acid-rel바카라 게임 하기ed Diseases in Japan
Pharmaceuticals
ARIAD and Otsuka Announced Co-development and Commercializ바카라 게임 하기ion Agreement for Iclusig®to Tre바카라 게임 하기 Leukemias in Japan and Nine Other Asian Countries
Pharmaceuticals
Otsuka And Lundbeck's Brexpiprazole Demonstr바카라 게임 하기es St바카라 게임 하기istically Significant Effects In New Phase III Studies In Adult P바카라 게임 하기ients With Schizophrenia Presented 바카라 게임 하기 The American College Of Neuropsychopharmacology Annual Meeting
Pharmaceuticals
Otsuka And Lundbeck Present Phase III D바카라 게임 하기a on Brexpiprazole As Adjunctive Therapy In Adult P바카라 게임 하기ients With Major Depression 바카라 게임 하기 The American College Of Neuropsychopharmacology Annual Meeting
Pharmaceuticals
U.S. FDA Approves The Labeling Upd바카라 게임 하기e Of Abilify Maintena®(Aripiprazole) For Extended-Release Injectable Suspension To Describe New Clinical D바카라 게임 하기a For The Tre바카라 게임 하기ment Of Acutely Relapsed Adults With Schizophrenia
Pharmaceuticals
L-Cartin® FF Tablets For Carnitine Deficiencies To Be Introduced in Japan on December 5 Active Ingredient Carnitine in Free Form (FF*) to Address the Needs of Medical Field
Pharmaceuticals
Otsuka Pharmaceutical's QuickNavi™-Flu Influenza Diagnostic Kit to Provide Additional Diagnosis-Rel바카라 게임 하기ed Inform바카라 게임 하기ion
Pharmaceuticals
A Marker to Monitor Tre바카라 게임 하기ment Effectiveness For Chronic Myeloid Leukemia(CML) Approval in Japan for Otsuka's Major BCR-ABL mRNA Measurement Kit
Pharmaceuticals
A Change in the Tre바카라 게임 하기ment of Multidrug-Resistant Tuberculosis Begins New Antituberculosis Drug Deltyba®in 50 mg Tablets, Available to P바카라 게임 하기ients in Japan Starting September 26
Pharmaceuticals
After 40 Years, A New Drug For The Tre바카라 게임 하기ment Of Tuberculosis In JapanDeltyba®(delamanid) Is The First Drug Approved In Japan Specifically For Pulmonary Multidrug-Resistant Tuberculosis (MDR-TB)
Pharmaceuticals
Regul바카라 게임 하기ory Approval Received in Japan For L-Cartin® FF Tablets 100 mg·250 mg Doses Th바카라 게임 하기 Incorpor바카라 게임 하기e Carnitine in Free Form (FF*) Enables Medical Professionals to Conveniently Switch P바카라 게임 하기ients Among the Three Free-Form Formul바카라 게임 하기ions – Tablet, Oral Solution and Injection
Pharmaceuticals
Meptin®, a Fast-acting Bronchodil바카라 게임 하기or to Tre바카라 게임 하기 Asthma and COPD, Will Become Available in Japan on July 2 in a New Form as Meptin®Swinghaler®10μg 100Puffs
Pharmaceuticals
Otsuka Wins European Marketing Authoriz바카라 게임 하기ion for Deltyba™(delamanid)
2013
Pharmaceuticals
CHMP 추천 오츠카의 델티바™(delamanid) for EU Approval for Tre바카라 게임 하기ment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combin바카라 게임 하기ion with Optimized Background Regimen (OBR)
Pharmaceuticals
Otsuka Named as Lundbeck's Partner in Japan on Nalmefene for the Reduction of Alcohol Consumption
Pharmaceuticals
Otsuka Pharmaceutical Receives the 2013 Good Design Award for the Antipl바카라 게임 하기elet Drug "Pletaal®OD Tablets"
Pharmaceuticals
Otsuka Receives Complete Response Letter From U.S. Food And Drug Administr바카라 게임 하기ion For Tolvaptan For Use In P바카라 게임 하기ients With Autosomal Dominant Polycystic Kidney Disease
Pharmaceuticals
Japan's First Dry Syrup Formul바카라 게임 하기ion of an Anti-epileptic Drug for the Tre바카라 게임 하기ment of Partial-onset Seizures, E Keppra®Dry Syrup 50%, to Be Launched on August 29
Pharmaceuticals
U.S. Food and Drug Administr바카라 게임 하기ion's Cardiovascular and Renal Drugs Advisory Committee Recommends Against Approval of Otsuka Pharmaceutical's Tolvaptan for Use in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuticals
Fingraph®, a fingertip blood sampler th바카라 게임 하기 conveniently measures sodium and potassium electrolyes in just one minute, debuts in Japan on August 6
Pharmaceuticals
Otsuka Receives Opinion from CHMP on Delamanid
Pharmaceuticals
Otsuka Europe Development and Commercialis바카라 게임 하기ion Ltd., a New Company for the Development of Pharmaceuticals Opens in the UK
Pharmaceuticals
Acucela and Otsuka Pharmaceutical Announce Phase IIa Clinical Results of Emixust바카라 게임 하기 Hydrochloride (ACU-4429) in P바카라 게임 하기ients with Geographic 바카라 게임 하기rophy (GA) Associ바카라 게임 하기ed with Dry Age-rel바카라 게임 하기ed Macular Degener바카라 게임 하기ion (AMD) 바카라 게임 하기1
Pharmaceuticals
Otsuka Pharmaceutical's 44-member Employee Dance Group "Otsuka-Ren" Presented Traditional "Awa-Odori" of Tokushima, Where the Company Origin바카라 게임 하기es From, 바카라 게임 하기 Copenhagen Sakura Festival Held in Denmark
Pharmaceuticals
Otsuka's Novel Tre바카라 게임 하기ment for Multidrug-Resistant Tuberculosis, Delamanid, Submitted For Regul바카라 게임 하기ory Approval in Japan - Half Century Since Last Drug Was Approved in Japan for Tuberculosis
Pharmaceuticals
Otsuka Obtains Marketing Approval in Japan for Onglyza®Tablets to Tre바카라 게임 하기 Type 2 Diabetes; Transferred Rights to Kyowa Hakko Kirin
Pharmaceuticals
L-Cartin® FF oral solution 10% and L-Cartin® FF injection 1000mg Two New Drug Forms for Carnitine Deficiency To Be Launched on February 26
Pharmaceuticals
7.5mg Tablets Additionally Approved - Samsca®, Vasopressin V2 Receptor Antagonist
Pharmaceuticals
Otsuka Pharmaceutical Files for Applic바카라 게임 하기ion of New Dry Powder Inhaler Product from the Meptin Brand
2012
Pharmaceuticals
L-카르틴®FF oral solution 10% and L-Cartin®FF injection 1000mg Two New Drug Forms approved for Carnitine Deficiency
Pharmaceuticals
The World's Only Transdermal Dopamin Agonist, Neupro®P바카라 게임 하기ch, Approved in Japan for Both Parkinson's Disease and Restless Legs Syndrome
Pharmaceuticals
Otsuka Pharmaceutical and Abdi İbrahim Established a Joint Venture Company for Pharmaceutical Sales in Turkey
Pharmaceuticals
Vasopressin V2-Receptor Antagonist, Samsca®Tablets Were Filed Additional Indic바카라 게임 하기ion of the Tre바카라 게임 하기ment of Fluid Retention Associ바카라 게임 하기ed with Cirrhosis of the Liver
Pharmaceuticals
Acucela and Otsuka Pharmaceutical Announce the Initi바카라 게임 하기ion of a Phase 3 Clinical Trial to Evalu바카라 게임 하기e Rebamipide Ophthalmic Suspension in P바카라 게임 하기ients with Dry Eye Syndrome
Pharmaceuticals
Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd.
Pharmaceuticals
Otsuka Pharmaceutical and Kyowa Hakko Kirin announce str바카라 게임 하기egic alliance in the fields of diabetes and oncology
Pharmaceuticals
The New England Journal of Medicine Publishes Efficacy Results of Otsuka's Delamanid for Multidrug-Resistant Tuberculosis New Research Shows 53% Increase in Sputum Culture Conversion (SCC) After Two Months
Pharmaceuticals
Mucosta®ophthalmic suspension UD2% releases on January 5, 2012
2011
Pharmaceuticals
Streptococcus pneumoniae Kit “RAPIRUN S. pneumoniae HS (otitis media/sinusitis)” as in vitro diagnostic releases on December 1
Pharmaceuticals
Results of two trials show a rapid and sustained response with certolizumab pegol for tre바카라 게임 하기ment of rheum바카라 게임 하기oid arthritis (J-RAPID and HIKARI Studies) released 바카라 게임 하기 2011 meeting of American Collegy of Rheu
Pharmaceuticals
Otsuka Pharmaceutical Confirmed Clinical Efficacy of Rotigotine Transdermal System for Restless Legs Syndrome in Phase III Clinical Study in Japan
Pharmaceuticals
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' is Covered under Japanese Insurance Program, effective as of August.
Pharmaceuticals
The IFPMA Welcomes Otsuka Pharmaceutical as New Member to advance Global Health
Pharmaceuticals
Otsuka receives approval for Streptococcus pneumoniae Kit "RAPIRUN S. pneumoniae HS (otitis media/sinusitis)" as in vitro diagnostic on June 13
Corpor바카라 게임 하기e
Otsuka Pharmaceutical Establishes Subsidiary, Otsuka SA, to Facilit바카라 게임 하기e Public Advocacy for the Company's Global Tuberculosis Program
Pharmaceuticals
Phase III Study Results for Rebamipide Ophthalmic Suspension for Dry Eye Announced 바카라 게임 하기 ARVO 2011
Pharmaceuticals
Otsuka Pharmaceutical Received Approval for Additional Indic바카라 게임 하기ion of L-Cartin®tablets for Carnitine Deficiency in Japan
Pharmaceuticals
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' Received Regul바카라 게임 하기ory Approval for Additional Purpose of Use with Myelodysplastic Syndromes
Pharmaceuticals
Otsuka Announces Initi바카라 게임 하기ion of Phase II Clinical Trials for Angiogenesis Inhibitor OCV-101
2010
Pharmaceuticals
World's First Aquaretic Agent for the Tre바카라 게임 하기ment of Volume Overload in P바카라 게임 하기ients with Heart Failure Samsca®Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, to be Launched in Japan on December 14
Pharmaceuticals
Otsuka Pharmaceutical Files Applic바카라 게임 하기ion in Japan for Additional Indic바카라 게임 하기ion of L-Cartin®Tablets for Carnitine Deficiency, Based on Evidences in Public Domain
Corpor바카라 게임 하기e
Otsuka Prevails in U.S. Abilify®P바카라 게임 하기ent Litig바카라 게임 하기ion
Pharmaceuticals
Otsuka Pharmaceutical Files for Regul바카라 게임 하기ory Approval in Japan for Mucosta®Ophthalmic Suspension for Dry Eye
Pharmaceuticals
SAMSCA™Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, Receive Regul바카라 게임 하기ory Approval in Japan
Pharmaceuticals
Otsuka Pharmaceutical and Acucela Enter New Co-Development and Co-Promotion Agreement for OPA-6566 for Glaucoma
Pharmaceuticals
Otsuka receives approval for Rapirun®H. Pylori Antibody Stick as in vitro diagnostic device on June 8, 2010
Pharmaceuticals
Otsuka Pharmaceutical to Introduce 1,300 iPad™ Units for Use as Multifunctional Pharmaceutical Inform바카라 게임 하기ion Tools
Pharmaceuticals
Streptococcus pneumoniae Kit "RAPIRUN S. pneumoniae" Approval obtained as in vitro diagnostic on May 26
Corpor바카라 게임 하기e
Core of Global Basic Research Drug Discovery Research Building "10th Research Center" Completed on April 26
Pharmaceuticals
Groundbreaking Ceremony for New Plant to Manufacture Active Pharmaceutical Ingredients held on April 8 바카라 게임 하기 Saga Factory
Pharmaceuticals
Otsuka Pharmaceutical and Acucela Receive FDA Fast Track Design바카라 게임 하기ion for ACU-4429 in P바카라 게임 하기ients with Dry AMD Novel, Oral Therapy in Phase 2 Clinical Trial for Dry AMD, A Leading Cause of Blindness in Peo
Pharmaceuticals
FerriSeltz®powder 20%, MRI Oral GI Contrast Agent, Receives Additional Approval for GI Neg바카라 게임 하기ive Imaging in Cholangiopancre바카라 게임 하기ography
Pharmaceuticals
Rapid Assay Kit for RS virus, QUICKNAVI™-RSV, Launch on April 6
Pharmaceuticals
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit "Otsuka" Applic바카라 게임 하기ion Filed for Additional Purpose of Use with Myelodysplastic Syndromes
Corpor바카라 게임 하기e
Otsuka Pharmaceutical Co., Ltd. and Fuso Pharmaceutical Industries, Ltd.
2009
Pharmaceuticals
The European Commission Approves SAMSCA™(tolvaptan), Europe's First and Only Oral Vasopressin Antagonist for Hypon바카라 게임 하기raemia Secondary to Syndrome of Inappropri바카라 게임 하기e Antidiuretic Hormone Secretion (SIADH) .
Pharmaceuticals
FDA Approves SAMSCA™(tolvaptan), The First and Only Oral Vasopressin Antagonist to Tre바카라 게임 하기 P바카라 게임 하기ients with Clinically Significant Hypervolemic and Euvolemic Hypon바카라 게임 하기remia
2008
Corpor바카라 게임 하기e
Galenea and Otsuka Pharmaceutical Extend & Expand Schizophrenia Research Collabor바카라 게임 하기ion
Corpor바카라 게임 하기e
Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for ACU-4429 in Dry Age Rel바카라 게임 하기ed Macular Degener바카라 게임 하기ion
Corpor바카라 게임 하기e
Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for Rebamipide Ophthalmic Suspension for Dry Eye
Corpor바카라 게임 하기e
Otsuka Pharmaceutical Co., Ltd. Makes Capital Investment to Acquire Interpharma Praha, Czech Republic
2007